Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice

Benoît Souchet, Mickael Audrain, Jean Marie Billard, Julien Dairou, Romain Fol, Nicola Salvatore Orefice, Satoru Tada, Yuchen Gu, Gaelle Dufayet-Chaffaud, Emmanuelle Limanton, François Carreaux, Jean Pierre Bazureau, Sandro Alves, Laurent Meijer, Nathalie Janel, Jérôme Braudeau, Nathalie Cartier

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Recent evidences suggest the involvement of DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1 A) in Alzheimer's disease (AD). Here we showed that DYRK1A undergoes a proteolytic processing in AD patients hippocampus without consequences on its kinase activity. Resulting truncated forms accumulate in astrocytes and exhibit increased affinity towards STAT3ɑ, a regulator of inflammatory process. These findings were confirmed in APP/PS1 mice, an amyloid model of AD, suggesting that this DYRK1A cleavage is a consequence of the amyloid pathology. We identified in vitro the Leucettine L41 as a compound able to prevent DYRK1A proteolysis in both human and mouse protein extracts. We then showed that intraperitoneal injections of L41 in aged APP/PS1 mice inhibit STAT3ɑ phosphorylation and reduce pro-inflammatory cytokines levels (IL1- β, TNF-ɑ and IL-12) associated to an increased microglial recruitment around amyloid plaques and decreased amyloid-β plaque burden. Importantly, L41 treatment improved synaptic plasticity and rescued memory functions in APP/PS1 mice. Collectively, our results suggest that DYRK1A may contribute to AD pathology through its proteolytic process, reducing its kinase specificity. Further evaluation of inhibitors of DYRK1A truncation promises a new therapeutic approach for AD.

Original languageEnglish
Pages (from-to)46
Number of pages1
JournalActa neuropathologica communications
Issue number1
StatePublished - 18 Mar 2019
Externally publishedYes


  • Alzheimer’s disease
  • DYRK1A
  • Kinase specificity
  • Proteolysis
  • Therapeutic approach


Dive into the research topics of 'Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice'. Together they form a unique fingerprint.

Cite this